COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
28
07
2021
accepted:
05
10
2021
revised:
29
09
2021
pubmed:
3
11
2021
medline:
15
12
2021
entrez:
2
11
2021
Statut:
ppublish
Résumé
Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41-0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02-1.04; HR = 1.79, 95% CI:1.04-3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.
Identifiants
pubmed: 34725454
doi: 10.1038/s41375-021-01450-8
pii: 10.1038/s41375-021-01450-8
pmc: PMC8559135
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3444-3454Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021. The Author(s).
Références
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–33.
doi: 10.1056/NEJMoa2001017
Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: a federated electronic medical record analysis. PLoS Med. 2020;17:e1003321.
doi: 10.1371/journal.pmed.1003321
Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–6.
doi: 10.1038/s41586-020-2521-4
Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881–92.
doi: 10.1182/blood.2020008824
Yigenoglu TN, Ata N, Altuntas F, Basci S, Dal MS, Korkmaz S, et al. The outcome of COVID-19 in patients with hematological malignancy. J Med Virol. 2021;93:1099–104.
doi: 10.1002/jmv.26404
Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7:e737–e45.
doi: 10.1016/S2352-3026(20)30251-9
Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105:1684–92.
doi: 10.1038/bjc.2011.450
Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015;126:573–81.
doi: 10.1182/blood-2015-03-567388
Tadmor T, Welslau M, Hus I. A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia. Expert Rev Hematol. 2018;11:57–70.
doi: 10.1080/17474086.2018.1407645
England JT, Abdulla A, Biggs CM, Lee AYY, Hay KA, Hoiland RL, et al. Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes. Blood Rev. 2021;45:100707.
doi: 10.1016/j.blre.2020.100707
Martin-Moro F, Marquet J, Piris M, Michael BM, Saez AJ, Corona M, et al. Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies. Br J Haematol. 2020;190:e16–e20.
doi: 10.1111/bjh.16801
He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, et al. COVID-19 in persons with haematological cancers. Leukemia. 2020;34:1637–45.
doi: 10.1038/s41375-020-0836-7
Cuneo A, Scarfo L, Reda G, Varettoni M, Quaglia FM, Marchetti M, et al. Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report. Blood. 2020;136:763–6.
doi: 10.1182/blood.2020006854
Scarfo L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020;34:2354–63.
doi: 10.1038/s41375-020-0959-x
Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136:1134–43.
doi: 10.1182/blood.2020006965
Roeker LE, Scarfo L, Chatzikonstantinou T, Abrisqueta P, Eyre TA, Cordoba R, et al. Worldwide examination of patients with CLL hospitalized for COVID-19. Blood 2020;136 Supplement 1:45–9.
doi: 10.1182/blood-2020-136408
Rawstron AC, Shanafelt T, Lanasa MC, Landgren O, Hanson C, Orfao A, et al. Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL). Cytom B Clin Cytom. 2010;78 Suppl 1:S19–23.
doi: 10.1002/cyto.b.20533
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018;131:2745–60.
doi: 10.1182/blood-2017-09-806398
Kosmidis Ι. brglm: bias reduction in binary-response generalized linear models. R package version 0.7.2. 2021 https://cran.r-project.org/package=brglm .
Therneau MT, Grambsch MP. Modeling survival data: extending the cox model. New York: Springer; 2000.
Kassambara A, Kosinski M, Biecek P. survminer: Drawing Survival Curves using ‘ggplot2’. R package version 0.4.9. 2021. https://CRAN.Rproject.org/package=survminer .
Wickham H. ggplot2: elegant graphics for data analysis. New York: Springer-Verlag; 2016.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–42.
doi: 10.1001/jama.2020.2648
Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA 2020;323:2052–9.
doi: 10.1001/jama.2020.6775
Treon SP, Castillo JJ, Skarbnik AP, Soumerai JD, Ghobrial IM, Guerrera ML, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020;135:1912–5.
doi: 10.1182/blood.2020006288
American Society of Hematology (ASH). COVID-19 and CLL: frequently asked questions. ASH; 2021. https://www.hematology.org/covid-19/covid-and-cll .
Macedo A, Goncalves N, Febra C. COVID-19 fatality rates in hospitalized patients: systematic review and meta-analysis. Ann Epidemiol. 2021;57:14–21.
doi: 10.1016/j.annepidem.2021.02.012
Finelli L, Gupta V, Petigara T, Yu K, Bauer KA, Puzniak LA. Mortality among US patients hospitalized with SARS-CoV-2 infection in 2020. JAMA Netw Open. 2021;4:e216556.
doi: 10.1001/jamanetworkopen.2021.6556
Investigators R-C, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, et al. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. N Engl J Med. 2021;384:1491–502.
doi: 10.1056/NEJMoa2100433
Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020;370:m2980.
doi: 10.1136/bmj.m2980